{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:06:47Z","timestamp":1696878407197},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00415-006-5008-9","type":"journal-article","created":{"date-parts":[[2006,9,24]],"date-time":"2006-09-24T19:40:15Z","timestamp":1159126815000},"page":"v59-v63","source":"Crossref","is-referenced-by-count":9,"title":["Therapy of immune neuropathies with intravenous immunoglobulins"],"prefix":"10.1007","volume":"253","author":[{"given":"Ralf","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5008_CR1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/IAI.69.4.2462-2469.2001","volume":"69","author":"Ang","year":"2001","unstructured":"Ang CW, De Klerk MA, Endtz HP et al. (2001) Guillain-Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM(1) and anti-GQ(1b) antibodies in rabbits. Infect Immun 69:2462\u20132469","journal-title":"Infect Immun"},{"key":"5008_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","volume":"44","author":"Azulay","year":"1994","unstructured":"Azulay JP, Blin O, Pouget J et al. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 44:429\u2013432","journal-title":"Neurology"},{"key":"5008_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"Buchwald","year":"2002","unstructured":"Buchwald B, Ahangari R, Weishaupt A, Toyka KV (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 51:673\u2013680","journal-title":"Ann Neurol"},{"key":"5008_CR4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"Comi","year":"2002","unstructured":"Comi G, Roveri L, Swan A et al. (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370\u20131377","journal-title":"J Neurol"},{"key":"5008_CR5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.59.12_suppl_6.S13","volume":"59","author":"Dalakas","year":"2002","unstructured":"Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59:S13\u2013S21","journal-title":"Neurology"},{"key":"5008_CR6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"Dalakas","year":"1996","unstructured":"Dalakas MC, Quarles RH, Farrer RG et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792\u2013795","journal-title":"Ann Neurol"},{"key":"5008_CR7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838\u2013845","journal-title":"Ann Neurol"},{"key":"5008_CR8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256\u20131262","journal-title":"Neurology"},{"key":"5008_CR9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.2414848","volume":"230","author":"Fujinami","year":"1985","unstructured":"Fujinami RS, Oldstone MBA (1985) Aminoacid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043\u20131045","journal-title":"Science"},{"key":"5008_CR10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","volume":"2","author":"Gold","year":"2003","unstructured":"Gold R, Dalakas MC, Toyka KV (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology 2:22\u201332","journal-title":"Lancet Neurology"},{"key":"5008_CR11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archneur.59.5.766","volume":"59","author":"Gorson","year":"2002","unstructured":"Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766\u2013772","journal-title":"Arch Neurol"},{"key":"5008_CR12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"Hadden","year":"1998","unstructured":"Hadden RD, Cornblath DR, Hughes RA et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780\u2013788","journal-title":"Ann Neurol"},{"key":"5008_CR13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy\u2014A double-blind, placebo-controlled, cross-over study. Brain 119:1067\u20131077","journal-title":"Brain"},{"key":"5008_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mus.880180203","volume":"18","author":"Hartung","year":"1995","unstructured":"Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barr\u00e9 syndrome. Part I Muscle Nerve 18:154\u2013164","journal-title":"Muscle Nerve"},{"key":"5008_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195\u2013201","journal-title":"Ann Neurol"},{"key":"5008_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0165-5728(99)00195-2","volume":"100","author":"Hughes","year":"1999","unstructured":"Hughes RA, Hadden RD, Gregson NA, Smith KJ (1999) Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 100:74\u201397","journal-title":"J Neuroimmunol"},{"key":"5008_CR17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","volume":"30","author":"Kieseier","year":"2004","unstructured":"Kieseier BC, Kiefer R, Gold R et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131\u2013156","journal-title":"Muscle Nerve"},{"key":"5008_CR18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1212\/WNL.57.4.686","volume":"57","author":"Koga","year":"2001","unstructured":"Koga M, Yuki N, Tai T, Hirata K (2001) Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 57:686\u2013691","journal-title":"Neurology"},{"key":"5008_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"Korinthenberg","year":"2005","unstructured":"Korinthenberg R, Schessl J, Kirschner J, Monting JS (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: A randomized trial. Pediatrics 116:8\u201314","journal-title":"Pediatrics"},{"key":"5008_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1471-4914(00)01909-2","volume":"7","author":"Lassmann","year":"2001","unstructured":"Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115\u201312","journal-title":"Trends Mol Med"},{"key":"5008_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger","year":"2001","unstructured":"Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145\u2013153","journal-title":"Brain"},{"key":"5008_CR22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jnnp.63.1.28","volume":"63","author":"Mariette","year":"1997","unstructured":"Mariette X, Chastang C, Clavelou P et al. (1997) A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 63:28\u201334","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5008_CR23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"Mendell","year":"2001","unstructured":"Mendell JR, Barohn RJ, Freimer ML et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445\u2013449","journal-title":"Neurology"},{"key":"5008_CR24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group (1997) Comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. Lancet 349:225\u2013230","journal-title":"Lancet"},{"key":"5008_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"Raphael","year":"2001","unstructured":"Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psych 71:235\u2013238","journal-title":"J Neurol Neurosurg Psych"},{"key":"5008_CR26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"Renaud","year":"2003","unstructured":"Renaud S, Gregor M, Fuhr P et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611\u2013615","journal-title":"Muscle Nerve"},{"key":"5008_CR27","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","volume":"63","author":"Ruegg","year":"2004","unstructured":"Ruegg SJ, Fuhr P, Steck AJ (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63:2178\u20132179","journal-title":"Neurology"},{"key":"5008_CR28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"Shevach","year":"2002","unstructured":"Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389\u2013400","journal-title":"Nat Rev Immunol"},{"key":"5008_CR29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/mus.880160113","volume":"16","author":"Simmons","year":"1993","unstructured":"Simmons Z, Bromberg MB, Feldman EL, Blaivas M (1993) Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 16:77\u201383","journal-title":"Muscle Nerve"},{"key":"5008_CR30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.56.6.661","volume":"56","author":"Stangel","year":"1999","unstructured":"Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56:661\u2013663","journal-title":"Arch Neurol"},{"key":"5008_CR31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","volume":"59","author":"Van den Berg","year":"1995","unstructured":"Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248\u2013252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5008_CR32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"van der Meche","year":"1992","unstructured":"van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326:1123\u20131129","journal-title":"N Engl J Med"},{"key":"5008_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","volume":"40","author":"van Doorn","year":"1990","unstructured":"van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study (see comments). Neurology 40:209\u2013212","journal-title":"Neurology"},{"key":"5008_CR34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00019052-200410000-00011","volume":"17","author":"van Doorn","year":"2004","unstructured":"van Doorn PA, Ruts L (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17:607\u2013613","journal-title":"Curr Opin Neurol"},{"key":"5008_CR35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"Van Koningsveld","year":"2004","unstructured":"Van Koningsveld R, Schmitz PIM, van der Meche FGA et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192\u2013196","journal-title":"Lancet"},{"key":"5008_CR36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"Vermeulen","year":"1993","unstructured":"Vermeulen M, van Doorn PA, Brand A et al. (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36\u201339","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5008_CR37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/brain\/118.4.841","volume":"118","author":"Visser","year":"1995","unstructured":"Visser LH, van der Meche FG, van Doorn PA et al. (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barre Study Group. Brain 118:841\u2013847","journal-title":"Brain"},{"key":"5008_CR38","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"Willison","year":"2002","unstructured":"Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591\u20132625","journal-title":"Brain"},{"key":"5008_CR39","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1086\/513800","volume":"176","author":"Yuki","year":"1997","unstructured":"Yuki N (1997) Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barre syndrome and Miller Fisher syndrome. J Infect Dis 176:S150\u2013S153","journal-title":"J Infect Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-5008-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5008-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:08:07Z","timestamp":1559070487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-5008-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":39,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["5008"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-5008-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}